What’s the current market cap for Hansa Biopharma AB stock?

Hansa Biopharma AB (HNSA) has a market cap of Skr3.5bn as of July 04, 2026.

What is the P/E ratio for Hansa Biopharma AB stock?

The price to earnings (P/E) ratio for Hansa Biopharma AB (HNSA) stock is 0 as of July 04, 2026.

Does Hansa Biopharma AB stock pay dividends?

No, Hansa Biopharma AB (HNSA) stock does not pay dividends to its shareholders as of July 04, 2026.

When is the next Hansa Biopharma AB dividend payment date?

Hansa Biopharma AB (HNSA) stock does not pay dividends to its shareholders.

What is the beta indicator for Hansa Biopharma AB?

Hansa Biopharma AB (HNSA) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Hansa Biopharma AB stock | SkrHNSA Share Price

07:00

09:05

11:15

13:20

15:25

About Hansa Biopharma AB

Hansa Biopharma AB is a biopharmaceutical company headquartered in Lund, Sweden, operating within the healthcare industry. The company specializes in developing immunomodulatory enzyme technology to treat rare immunological conditions. Its leading product, Idefirix, is designed to enable kidney transplants in highly sensitized patients by cleaving immunoglobulin G antibodies. Hansa Biopharma's strategic focus includes expanding its technology platform and gaining regulatory approvals internationally. The company's innovative approach in enzyme-based therapies positions it to address unmet medical needs in transplantation and autoimmunity.

Ticker

Skr HNSA

Sector

Health

Primary listing

XSTO

Employees

122

Headquarters

Lund, Sweden

Website

www.hansabiopharma.com

HNSA Metrics

BasicAdvanced

kr 3.5bn

-kr 7.71

1.50

Bulls say / Bears say

Hansa entered a €115 M licensing agreement with SERB for Idefirix in Europe and MENA, receiving €110 M upfront and enhancing its cash runway ahead of a planned U.S. launch (Reuters)

The FDA accepted Hansa’s Biologics License Application for imlifidase on February 18, 2026, de-risking its U.S. regulatory pathway and setting the stage for a potential approval decision (Reuters)

Jefferies initiated coverage with a Buy rating and a SEK 100 price target, citing Idefirix’s expanding real-world validation in Europe and a de-risked U.S. launch following a positive pivotal readout (Reuters)

Jefferies notes that Germany’s pause of its highly sensitized prioritization program could limit near-term uptake of Idefirix in a key EU market (Reuters)

In Q1 2026 Hansa reported a widened operating loss of SEK 142.5 M and a 48% revenue decline to SEK 34.6 M, underscoring persistent profitability challenges (Reuters)

The FDA has assigned a PDUFA action date of December 19, 2026 for the imlifidase BLA, leaving significant regulatory uncertainty and potential delays to the U.S. approval timeline (Nasdaq)

Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Bulls say / Bears say

Hansa entered a €115 M licensing agreement with SERB for Idefirix in Europe and MENA, receiving €110 M upfront and enhancing its cash runway ahead of a planned U.S. launch (Reuters)

The FDA accepted Hansa’s Biologics License Application for imlifidase on February 18, 2026, de-risking its U.S. regulatory pathway and setting the stage for a potential approval decision (Reuters)

Jefferies notes that Germany’s pause of its highly sensitized prioritization program could limit near-term uptake of Idefirix in a key EU market (Reuters)

In Q1 2026 Hansa reported a widened operating loss of SEK 142.5 M and a 48% revenue decline to SEK 34.6 M, underscoring persistent profitability challenges (Reuters)

The FDA has assigned a PDUFA action date of December 19, 2026 for the imlifidase BLA, leaving significant regulatory uncertainty and potential delays to the U.S. approval timeline (Nasdaq)

Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2026.

About Hansa Biopharma AB

Ticker

Primary listing

Employees

Headquarters

HNSA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Skr HNSA

Lightyear

Legal

Work with us

Bulls say / Bears say

Hansa Biopharma AB/Skr HNSA

About Hansa Biopharma AB

Ticker

Primary listing

Employees

Headquarters

HNSA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

What’s the current market cap for Hansa Biopharma AB stock?

What is the P/E ratio for Hansa Biopharma AB stock?

Does Hansa Biopharma AB stock pay dividends?

When is the next Hansa Biopharma AB dividend payment date?

What is the beta indicator for Hansa Biopharma AB?

Bulls say / Bears say